Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LYNAVOY vs AURLUMYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LYNAVOY (mirdametinib) is an oral, reversible, allosteric inhibitor of MEK1 and MEK2, blocking downstream MAPK/ERK signaling pathway activation, thereby inhibiting tumor cell proliferation and survival.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
Treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
LYNAVOY (vitrakvi, larotrectinib) 100 mg orally twice daily, with or without food, until disease progression or unacceptable toxicity. For patients with body surface area <1.0 m2, the recommended dose is 100 mg/m2 per dose (maximum 100 mg per dose) twice daily.
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
Terminal elimination half-life is approximately 30–40 hours, supporting once-daily dosing. Steady-state is achieved within 2–3 weeks.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily metabolized by CYP3A4 and to a lesser extent by CYP2C8; undergoes glucuronidation by UGT1A9.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Primarily via bile into feces (approximately 77% of total clearance as unchanged drug and metabolites); renal excretion accounts for about 15% (less than 1% unchanged). A small amount is excreted in urine as metabolites.
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Approximately 94–96% bound to plasma proteins, primarily albumin.
Approximately 85-90% bound to serum albumin.
Apparent volume of distribution is about 50 L (approximately 0.7 L/kg), indicating extensive tissue distribution.
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Absolute oral bioavailability is approximately 70% under fasting conditions. Food does not significantly affect absorption.
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min) not on hemodialysis, reduce dose to 75 mg orally twice daily (adults) or 75 mg/m2 per dose (pediatric, max 75 mg per dose). End-stage renal disease on hemodialysis: no data, consider risks vs benefits.
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
Child-Pugh A: no adjustment. Child-Pugh B: reduce to 75 mg orally twice daily (adults) or 75 mg/m2 per dose (pediatric, max 75 mg per dose). Child-Pugh C: reduce to 50 mg orally twice daily (adults) or 50 mg/m2 per dose (pediatric, max 50 mg per dose).
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
For patients aged ≥28 days and <18 years with body surface area (BSA) ≥1.0 m2: 100 mg orally twice daily. For BSA <1.0 m2: 100 mg/m2 per dose (maximum 100 mg per dose) orally twice daily. Administer with or without food.
Not established; safety and efficacy not determined in pediatric patients.
No specific dose adjustment recommended. Clinical studies included patients ≥65 years; no overall differences in safety or efficacy observed. Monitor for adverse effects due to potential age-related comorbidities and renal/hepatic function decline.
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
None.
None.
Cardiomyopathy: Assess left ventricular ejection fraction (LVEF) before initiation, monitor during treatment, and withhold or permanently discontinue based on severity.,Ocular toxicity: Monitor for retinal vein occlusion, retinal pigment epithelial detachment, and visual disturbances; conduct ophthalmic evaluations.,Dermatologic toxicity: Manage rash, acneiform dermatitis, and hand-foot skin reactions with supportive care; dose interruption or reduction may be required.,Gastrointestinal toxicity: Diarrhea, nausea, vomiting, and stomatitis are common; manage with antiemetics and antidiarrheals.,Venous thromboembolism (VTE): Monitor for signs and symptoms; discontinue if life-threatening VTE occurs.,Rhabdomyolysis: Monitor creatine kinase (CK) levels; withhold if CK elevation with muscle symptoms occurs.,Embryo-fetal toxicity: Can cause fetal harm; advise females of reproductive potential and males with female partners of childbearing potential to use effective contraception.
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
None.
Hypersensitivity to AURLUMYN or any of its components.
No specific food interactions. Maintain adequate hydration. Avoid grapefruit juice if taking concomitant CYP3A4 substrates. No dietary restrictions required.
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
LYNAVOY (ribociclib) is contraindicated in pregnancy. Based on its mechanism of action (CDK4/6 inhibition) and animal studies, it can cause fetal harm. First trimester: High risk of embryotoxicity and teratogenicity; avoid pregnancy. Second and third trimesters: Continued risk; not recommended. Women of childbearing potential must use effective contraception during therapy and for at least 3 weeks after last dose.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
It is unknown if LYNAVOY is excreted in human milk; however, ribociclib and its metabolites are present in rat milk. Due to potential serious adverse effects in nursing infants, breastfeeding is not recommended during treatment and for at least 3 weeks after the last dose. M/P ratio not available.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
LYNAVOY is contraindicated in pregnancy and no dose adjustment recommendations exist. If a patient becomes pregnant during treatment, discontinue LYNAVOY immediately. No pharmacokinetic data are available to guide dose changes during pregnancy.
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
LYNAVOY (lutetium Lu 177 vipivotide tetraxetan) is a PSMA-targeted radioligand therapy for PSMA-positive metastatic castration-resistant prostate cancer. Requires premedication with antiemetics. Monitor for myelosuppression, xerostomia, and renal toxicity. Ensure adequate hydration prior to infusion. Contraindicated in severe bone marrow suppression.
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
You are receiving a radioactive drug that targets prostate cancer cells. You may experience dry mouth, nausea, or low blood counts.,Drink plenty of fluids before and after treatment to protect your kidneys.,Avoid close contact with pregnant women, infants, and children for a period of time as instructed by your healthcare team.,Use effective contraception during treatment and for several months after the last dose.,Report any signs of infection, bleeding, or unusual fatigue to your doctor immediately.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LYNAVOY vs AURLUMYN, answered by our medical review team.
LYNAVOY is a Antineoplastic Agent that works by LYNAVOY (mirdametinib) is an oral, reversible, allosteric inhibitor of MEK1 and MEK2, blocking downstream MAPK/ERK signaling pathway activation, thereby inhibiting tumor cell proliferation and survival.. AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LYNAVOY and AURLUMYN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LYNAVOY is: LYNAVOY (vitrakvi, larotrectinib) 100 mg orally twice daily, with or without food, until disease progression or unacceptable toxicity. For patients with body surface area <1.0 m2, the recommended dose is 100 mg/m2 per dose (maximum 100 mg per dose) twice daily.. The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LYNAVOY and AURLUMYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LYNAVOY is classified as Category C. LYNAVOY (ribociclib) is contraindicated in pregnancy. Based on its mechanism of action (CDK4/6 inhibition) and animal studies, it can cause fetal harm. First trimester: High risk o. AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.